Tian Chao, Deng Shizhou, Yang Ming, Bai Baochen, Wei Lai
Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine of Tsinghua University, Beijing 102218, China.
Ministry of Education Key Laboratory of Digital Intelligence Hepatology, Tsinghua University, Beijing 100084, China.
Genes Dis. 2025 Apr 24;12(6):101653. doi: 10.1016/j.gendis.2025.101653. eCollection 2025 Nov.
Chitinase-3-like protein 1 (CHI3L1) is part of the glycoside hydrolase family 18. Despite lacking enzymatic activity, its unique structure allows it to bind to ligands, altering its steric configuration to mediate cell proliferation, inflammation, fibrosis, and carcinogenesis. In liver disease, CHI3L1 serves as a common diagnostic biomarker for hepatitis-related fibrosis. Additionally, CHI3L1 can predict the risk of non-alcoholic steatohepatitis, the progression of hepatic fibrosis, and the prognosis of alcoholic liver disease and hepatocellular carcinoma. It also aids in diagnosing and staging non-alcoholic fatty liver disease-related and alcoholic liver disease-related fibrosis, and in monitoring hepatitis-related fibrosis treatment. Furthermore, CHI3L1 is secreted by various cells, including hepatocytes, hepatic stellate cells, macrophages, and mesenchymal stem cells, to regulate hepatic injury, fibrosis, steatosis, and hepatocellular carcinoma through different signaling pathways. This review highlights CHI3L1's dual roles as both a biomarker and regulator in various liver diseases, aiming to broaden researchers' understanding of its potential applications.
几丁质酶-3样蛋白1(CHI3L1)是糖苷水解酶家族18的一部分。尽管缺乏酶活性,但其独特的结构使其能够与配体结合,改变其空间构型以介导细胞增殖、炎症、纤维化和致癌作用。在肝脏疾病中,CHI3L1是肝炎相关纤维化的常见诊断生物标志物。此外,CHI3L1可以预测非酒精性脂肪性肝炎的风险、肝纤维化的进展以及酒精性肝病和肝细胞癌的预后。它还有助于诊断和分期非酒精性脂肪性肝病相关和酒精性肝病相关的纤维化,并监测肝炎相关纤维化的治疗。此外,CHI3L1由包括肝细胞、肝星状细胞、巨噬细胞和间充质干细胞在内的各种细胞分泌,通过不同的信号通路调节肝损伤、纤维化、脂肪变性和肝细胞癌。本综述强调了CHI3L1在各种肝脏疾病中作为生物标志物和调节剂的双重作用,旨在拓宽研究人员对其潜在应用的理解。
Genes Dis. 2025-4-24
Cochrane Database Syst Rev. 2016-3-2
Cochrane Database Syst Rev. 2015-1-22
2025-1
J Cancer Res Clin Oncol. 2013-3-23
Metabolism. 2016-8
Cell Mol Gastroenterol Hepatol. 2024
Lancet. 2023-9-23